SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced that one oral presentation and four posters, including data from the company’s Phase 3 clinical trial program of its lead drug candidate SILENOR™ (doxepin HCl) for the treatment of insomnia, will be presented at the 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS) in Baltimore, Maryland. The posters will be presented on Wednesday, June 11 (10:15 a.m. to 12:15 p.m. ET), and the oral presentation will be on Thursday, June 12 (8:00 a.m. to 8:15 a.m. ET). Data from these presentations are embargoed until they are presented.